肝細胞癌のソラフェニブ治療効果判定における RECIST, modified RECIST, RECICL 基準の比較

概要

論文の詳細を見る
RECIST, mRECIST and RECICL are criteria for evaluating the therapeutic response of hepatocellular carcinoma and there are several differences among these criteria. We investigated and compared differences in the response evaluation of sorafenib treatment. As a result, mRECIST and RECIST showed a 59% disease control rate, while RECICL and mRECIST showed an 11% response rate. In RECIST and mRECIST, CR/PR/SD groups demonstrated a significantly better prognosis (P=0.02) than PD. The SD group prognosis was significantly better (P=0.045) than that of the PD group in mRECIST. Multivariate analysis of factors contributing to survival yielded the following values: disease control of mRECIST or RECIST (P=0.005), Vp (P=0.008) and pre-treatment DCP (P=0.047). Concerning Sorafenib therapy, mRECIST tend to stratify the prognosis and was considered the most useful criteria at this time.
社団法人　日本肝臓学会の論文
2011-05-25